Expertise in
14
conditions

Dr. Crystal M. Proud

Pediatric Neurology | Pediatrics | Neurology
Childrens Specialty Group PLLC
850 Southampton Ave, 
Norfolk, VA 
Accepting New Patients
Offers Telehealth
16 Years of Experience
Expertise in
14
conditions
Childrens Specialty Group PLLC
850 Southampton Ave, 
Norfolk, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Crystal Proud is a Pediatric Neurologist and a Pediatrics provider in Norfolk, Virginia. Dr. Proud has been practicing medicine for over 16 years is highly rated in 14 conditions, according to our data. Her top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Spinal Muscular Atrophy Type 2. Dr. Proud is currently accepting new patients.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Neurology with Special Qualifications in Neurology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

CHILDRENS SPECIALTY GROUP PLLC
850 Southampton Ave, Norfolk, VA 23510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory
A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Genetic, Procedure
Study Phase: Phase 3
A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam
A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Other, Drug
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

20 Total Publications

Open-label phase 4 trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.
Open-label phase 4 trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.
Journal: The Journal of clinical investigation
Published: September 16, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Eric J. Goldberg
Neurology
Expertise in
18
conditions
Dr. Eric J. Goldberg
Neurology

Tidewater Neurologists Inc PC

3235 Academy Ave, Suite 305, 
Portsmouth, VA 
 (5.1 miles away)
757-686-9300
Languages Spoken:
English, Spanish
See accepted insurances

Eric Goldberg is a Neurologist in Portsmouth, Virginia. Dr. Goldberg is highly rated in 18 conditions, according to our data. His top areas of expertise are Stroke, Benign Rolandic Epilepsy, Trigeminal Neuralgia, and Migraine.

Expertise in
28
conditions
Dr. Daniel A. Graf
Neurology
Expertise in
28
conditions
Dr. Daniel A. Graf
Neurology

Sentara Medical Group

301 Riverview Ave, Suite 202a, 
Norfolk, VA 
 (0.1 miles away)
757-252-9015
Experience:
17+ years
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Graf is a Neurologist in Norfolk, Virginia. Dr. Graf has been practicing medicine for over 17 years is highly rated in 28 conditions, according to our data. His top areas of expertise are Seizures, Generalized Tonic-Clonic Seizure, Memory Loss, Unverricht-Lundborg Syndrome, and Adenoidectomy. Dr. Graf is currently accepting new patients.

Expertise in
43
conditions
Dr. Karen M. Thomas
Neurology
Expertise in
43
conditions
Dr. Karen M. Thomas
Neurology

Sentara Neurology Specialists

1950 Glenn Mitchell Drive, Suite 200, 
Virginia Beach, VA 
 (12.9 miles away)
757-507-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Karen Thomas is a Neurologist in Virginia Beach, Virginia. Dr. Thomas is highly rated in 43 conditions, according to our data. Her top areas of expertise are Parkinson's Disease, Movement Disorders, Essential Tremor, and Secondary Parkinsonism. Dr. Thomas is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Proud's expertise for a condition
ConditionClose
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile